ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. More Details
+ 1 more risk
Flawless balance sheet and overvalued.
Share Price & News
How has ABIONYX Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ABNX is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: ABNX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of French stocks.
7 Day Return
1 Year Return
Return vs Industry: ABNX underperformed the French Biotechs industry which returned 35.2% over the past year.
Return vs Market: ABNX underperformed the French Market which returned 48.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is ABIONYX Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
11 months ago | Simply Wall StCould ABIONYX Pharma SA's (EPA:ABNX) Investor Composition Influence The Stock Price?
1 year ago | Simply Wall StCan We See Significant Insider Ownership On The ABIONYX Pharma SA (EPA:ABNX) Share Register?
1 year ago | Simply Wall StSome ABIONYX Pharma (EPA:ABNX) Shareholders Have Copped A 96% Share Price Wipe Out
Is ABIONYX Pharma undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ABNX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ABNX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ABNX is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: ABNX is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: ABNX is unprofitable, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ABNX is good value based on its PB Ratio (3.3x) compared to the FR Biotechs industry average (4.3x).
How is ABIONYX Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ABNX's revenue is forecast to grow faster than the French market.
High Growth Revenue: Insufficient data to determine if ABNX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ABNX's Return on Equity is forecast to be high in 3 years time
How has ABIONYX Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABNX is currently unprofitable.
Growing Profit Margin: ABNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ABNX is unprofitable, but has reduced losses over the past 5 years at a rate of 53.9% per year.
Accelerating Growth: Unable to compare ABNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).
Return on Equity
High ROE: ABNX has a negative Return on Equity (-28.5%), as it is currently unprofitable.
How is ABIONYX Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ABNX's short term assets (€10.1M) exceed its short term liabilities (€3.5M).
Long Term Liabilities: ABNX's short term assets (€10.1M) exceed its long term liabilities (€117.0K).
Debt to Equity History and Analysis
Debt Level: ABNX's debt to equity ratio (16.5%) is considered satisfactory.
Reducing Debt: ABNX's debt to equity ratio has reduced from 1026.6% to 16.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABNX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ABNX has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 16.3% each year.
What is ABIONYX Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABNX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABNX's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Cyrille Tupin (44 yo)
Mr. Cyrille Tupin, CPA is Chief Executive Officer, General Manager and Director at ABIONYX Pharma SA since September 6, 2019. Mr. Tupin served as the Chief Financial and Administrative Officer at ABIONYX ...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Cyrille's total compensation is reasonable compared to companies of similar size in the French market.
Compensation vs Earnings: Insufficient data to compare Cyrille's compensation with company performance.
Experienced Management: ABNX's management team is considered experienced (4.3 years average tenure).
Experienced Board: ABNX's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.3%.
ABIONYX Pharma SA's company bio, employee growth, exchange listings and data sources
- Name: ABIONYX Pharma SA
- Ticker: ABNX
- Exchange: ENXTPA
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €25.098m
- Shares outstanding: 24.56m
- Website: https://abionyx.com
Number of Employees
- ABIONYX Pharma SA
- 33-43 av. Georges Pompidou – Bât. D2
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portf...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 17:51|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.